Divi’s Lab surges 4% afterTelangana unit completes USFDA inspection with no observations
Divi’s Laboratories rallied over 4 per cent after a unit in Telangana did not receive any 483 observations following an inspection by the US Food and Drug Administration. Reacting to this, the stock gained 4 per cent to hit an intraday high of Rs 1213. The stock settled at Rs 1166 on the BSE.
Divis Laboratories on Thursday said its unit at Choutuppal in Telangana has undergone successful inspection by the US health regulator with no observations. The companys unit-I at Choutuppal has had an inspection by the United States Food and Drug Administration (USFDA) from May 14-16, 2018, Divis Labs said in a filing to BSE.
"This was a general cGMP inspection by USFDA. The inspection has been concluded with no 483 observations," it added.
TRENDING NOW
As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company?s management of objectionable conditions at its facility.
WATCH ZEE BUSINESS VIDEO HERE
Shares of Divis Laboratories today closed at Rs 1,166.15 per scrip on BSE, up 1.50 per cent from the previous close.
04:48 pm
Top Gainers, Losers: IndusInd Bank gains on better revenue projection; Divi’s Labs cracks on Q3 miss — Check brokerage recommendation, target price
LIC’s shareholding in Divi’s Lab crosses 5%; stock down 13% in 2 sessions – brokerages recommend this
Nifty, Sensex Top Gainers and Losers: Markets react to Q2 results; Britannia, SBI gain most; Divis Lab among top losers – check targets
Top Loser Today: Divi’s Lab stock dips over 7% after weak Q2 results, hits 52-week low